Microglia are the resident immune cells of the central nervous system (CNS) and play critical roles in brain development, homeostasis, and immune surveillance. In neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), microglia become chronically activated and contribute to neuroinflammation, synaptic loss, and neuronal death. Microglial modulation therapy aims to redirect microglia from a pro-inflammatory (M1) phenotype to a neuroprotective (M2-like) phenotype, thereby reducing neurotoxicity while preserving essential immune functions[1].
Microglial modulation represents a promising therapeutic strategy that targets the neuroimmune axis of neurodegeneration. Rather than broadly suppressing microglial activity—which could compromise essential brain immune functions—modern approaches seek to selectively modulate microglial phenotype and function. This includes enhancing phagocytic clearance of pathological proteins, reducing pro-inflammatory cytokine production, promoting neurotrophic factor release, and supporting synaptic maintenance[2].
The challenge of microglial modulation lies in the complex and context-dependent nature of microglial activation. Microglia can adopt diverse phenotypes in response to different environmental signals, and the same molecule may have opposing effects depending on disease stage, brain region, and individual genetic factors.
Microglia exhibit remarkable phenotypic plasticity, traditionally categorized along a spectrum:
M1 (Classically Activated): Pro-inflammatory phenotype characterized by production of cytokines such as IL-1β, IL-6, TNF-α, and nitric oxide. M1 microglia are associated with synaptic pruning, demyelination, and neuronal loss in neurodegenerative conditions[3].
M2 (Alternatively Activated): Anti-inflammatory and regenerative phenotype that produces anti-inflammatory cytokines (IL-10, TGF-β), neurotrophic factors (BDNF, IGF-1), and promotes tissue repair. M2-like microglia support amyloid clearance and synaptic plasticity[4].
Disease-Associated Microglia (DAM): A distinct phenotype identified in mouse models of AD, characterized by upregulation of genes involved in lipid metabolism and phagocytosis. DAM appear early in disease progression and may represent an attempt at protective response[5].
Microglia in ALS/PD: In ALS, activated microglia surround motor neurons and secrete pro-inflammatory mediators. In PD, microglia in the substantia nigra show chronic activation in response to α-synuclein aggregates[6].
Multiple signaling pathways regulate microglial activation:
| Pathway | Role | Therapeutic Target |
|---|---|---|
| TREM2 | Triggering receptor on myeloid cells 2; regulates phagocytosis | TREM2 agonists |
| CSF1R | Colony-stimulating factor 1 receptor; controls microglial survival | CSF1R antagonists |
| CX3CR1 | Fractalkine receptor; modulates neuroinflammation | CX3CR1 agonists |
| NLRP3 | Inflammasome; produces IL-1β, IL-18 | NLRP3 inhibitors |
| NF-κB | Master regulator of inflammatory gene expression | NF-κB inhibitors |
| TLR4 | Toll-like receptor 4; recognizes DAMPs | TLR4 antagonists |
TREM2 is a surface receptor on microglia that recognizes amyloid-beta, lipid droplets, and apoptotic cells, triggering phagocytosis. TREM2 variants (R47H, R62H) increase AD risk by approximately 3-4×, highlighting its protective role[7].
TREM2 Agonists:
These therapies aim to enhance microglial phagocytosis of amyloid plaques while promoting the DAM phenotype[8].
CSF1R signaling is essential for microglial survival and proliferation. CSF1R antagonists can reduce microglial numbers but may impair necessary immune surveillance.
Clinical Candidates:
The CX3CL1/CX3CR1 axis regulates microglial-neuronal communication. CX3CR1 deficiency in mice exacerbates neurodegeneration, suggesting protective effects of CX3CR1 signaling[9].
The NLRP3 inflammasome converts pro-IL-1β and pro-IL-18 into active forms, driving chronic neuroinflammation. NLRP3 inhibitors are in development for multiple neurodegenerative conditions[10].
Clinical Candidates:
Bruton's tyrosine kinase (BTK) is expressed in microglia and regulates immune signaling. BTK inhibitors reduce microglial activation and have shown promise in MS and AD models[11].
Clinical Candidates:
Several tyrosine kinase inhibitors have shown microglial modulatory effects:
Multiple microglial modulatory approaches have reached clinical testing in AD:
| Agent | Target | Phase | Status |
|---|---|---|---|
| AL002 | TREM2 agonist | Phase 2 | Recruiting |
| Tolebrutinib | BTK inhibitor | Phase 2 | Recruiting |
| Dapansutrile | NLRP3 inhibitor | Phase 2 | Completed |
| Masitinib | CSF1R/TYK2 | Phase 3 | Ongoing |
In PD, microglial modulation aims to reduce α-synuclein-induced neuroinflammation:
Microglial activation surrounding motor neurons is a key pathological feature:
MS represents the most advanced area for microglial modulation:
The study of Microglial Modulation Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.